 "Aurobindo Pharma, Sandoz Inc mutually call off $900 mn deal of generic oral solids, dermatology businesses")
New Delhi: Aurobindo Pharma on Thursday said the $900 million deal to acquire Sandoz Inc’s US-based generic oral solids and dermatology businesses, has been mutually called off.
“The decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within anticipated timelines,” Aurobindo Pharma said in a regulatory filing.
In September 2018, Aurobindo Pharma had said its US subsidiary has entered into a pact to acquire commercial operations and three manufacturing facilities in America from Sandoz Inc, USA, for $900 million.
The acquisition was to be made through its wholly-owned subsidiary, Aurobindo Pharma USA Inc.
The transaction if completed would have positioned the Hyderabad-based firm as the second largest dermatology player and the second-largest generics company in the US by prescriptions.
 "This Week in Explainers: Will recession in UK, Japan hit daily living?")
 "FirstUp: Nitish Kumar to seek trust vote, RLD to formally join NDA… The big stories today")
 "This Week in Explainers: What Uttarakhand’s Uniform Civil Code means for live-in couples")
 "Ram mandir consecration: Did Nihang Sikhs start the temple movement over a century back?")
 "This Week in Explainers: Will recession in UK, Japan hit daily living?")
 "FirstUp: Nitish Kumar to seek trust vote, RLD to formally join NDA… The big stories today")
 "This Week in Explainers: What Uttarakhand’s Uniform Civil Code means for live-in couples")
 "Ram mandir consecration: Did Nihang Sikhs start the temple movement over a century back?")